中国前列腺癌:流行病学趋势、基因组学见解和优化管理的未来方向

IF 9.4 Q1 ONCOLOGY
Zhongyuan Wang , Wenhao Xu , Fangning Wan , Xi Tian , Aihetaimujiang Anwaier , Shiqi Ye , Siqi Zhou , Hailiang Zhang , Xiaojian Qin , Dingwei Ye
{"title":"中国前列腺癌:流行病学趋势、基因组学见解和优化管理的未来方向","authors":"Zhongyuan Wang ,&nbsp;Wenhao Xu ,&nbsp;Fangning Wan ,&nbsp;Xi Tian ,&nbsp;Aihetaimujiang Anwaier ,&nbsp;Shiqi Ye ,&nbsp;Siqi Zhou ,&nbsp;Hailiang Zhang ,&nbsp;Xiaojian Qin ,&nbsp;Dingwei Ye","doi":"10.1016/j.jncc.2025.05.002","DOIUrl":null,"url":null,"abstract":"<div><div>The incidence and mortality of prostate cancer (PCa) in China have risen sharply in recent years, posing an escalating public health concern. In contrast to Western populations, Chinese patients are more frequently diagnosed at advanced stages, often with metastatic disease and suboptimal survival outcomes. These disparities reflect intrinsic differences in epidemiological patterns, molecular landscapes, and healthcare delivery systems unique to the Chinese context. Nevertheless, prevailing PCa management paradigms, largely derived from Western-centric evidence, remain inadequately calibrated to the biological and clinical realities of Chinese patients. This review provides a comprehensive synthesis of the epidemiology, genomic alterations, clinical presentations, and treatment disparities of PCa in China, highlighting the urgent need for population-specific strategies. Priority areas include the development of ethnically optimized screening protocols, the integration of precision medicine approaches, and the implementation of regionally adapted prevention and early detection programs. Furthermore, expanding participation in clinical trials and accelerating translational research efforts, particularly in multi-omics and biomarker discovery, will be critical to bridging current gaps. By aligning emerging scientific innovations with localized healthcare needs, China holds the potential to reshape its prostate cancer care paradigm, improving outcomes, reducing disparities, and contributing to the global advancement of precision oncology.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"5 5","pages":"Pages 474-485"},"PeriodicalIF":9.4000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prostate cancer in China: epidemiological trends, genomic insights, and future directions for optimized management\",\"authors\":\"Zhongyuan Wang ,&nbsp;Wenhao Xu ,&nbsp;Fangning Wan ,&nbsp;Xi Tian ,&nbsp;Aihetaimujiang Anwaier ,&nbsp;Shiqi Ye ,&nbsp;Siqi Zhou ,&nbsp;Hailiang Zhang ,&nbsp;Xiaojian Qin ,&nbsp;Dingwei Ye\",\"doi\":\"10.1016/j.jncc.2025.05.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The incidence and mortality of prostate cancer (PCa) in China have risen sharply in recent years, posing an escalating public health concern. In contrast to Western populations, Chinese patients are more frequently diagnosed at advanced stages, often with metastatic disease and suboptimal survival outcomes. These disparities reflect intrinsic differences in epidemiological patterns, molecular landscapes, and healthcare delivery systems unique to the Chinese context. Nevertheless, prevailing PCa management paradigms, largely derived from Western-centric evidence, remain inadequately calibrated to the biological and clinical realities of Chinese patients. This review provides a comprehensive synthesis of the epidemiology, genomic alterations, clinical presentations, and treatment disparities of PCa in China, highlighting the urgent need for population-specific strategies. Priority areas include the development of ethnically optimized screening protocols, the integration of precision medicine approaches, and the implementation of regionally adapted prevention and early detection programs. Furthermore, expanding participation in clinical trials and accelerating translational research efforts, particularly in multi-omics and biomarker discovery, will be critical to bridging current gaps. By aligning emerging scientific innovations with localized healthcare needs, China holds the potential to reshape its prostate cancer care paradigm, improving outcomes, reducing disparities, and contributing to the global advancement of precision oncology.</div></div>\",\"PeriodicalId\":73987,\"journal\":{\"name\":\"Journal of the National Cancer Center\",\"volume\":\"5 5\",\"pages\":\"Pages 474-485\"},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Cancer Center\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266700542500050X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Center","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266700542500050X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

近年来,前列腺癌(PCa)在中国的发病率和死亡率急剧上升,引起了越来越多的公共卫生关注。与西方人群相比,中国患者更常被诊断为晚期,通常伴有转移性疾病和次优生存结果。这些差异反映了中国特有的流行病学模式、分子景观和医疗保健提供系统的内在差异。然而,目前流行的前列腺癌管理模式,主要来源于西方中心的证据,仍然不能充分适应中国患者的生物学和临床现实。本文综述了中国PCa的流行病学、基因组改变、临床表现和治疗差异,强调了针对人群的治疗策略的迫切需要。重点领域包括制定种族优化的筛查方案,整合精准医学方法,以及实施适合地区的预防和早期发现计划。此外,扩大临床试验的参与和加速转化研究的努力,特别是在多组学和生物标志物的发现方面,将对弥合目前的差距至关重要。通过将新兴的科学创新与本地化的医疗需求结合起来,中国有可能重塑其前列腺癌护理模式,改善结果,缩小差距,并为全球精准肿瘤学的进步做出贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prostate cancer in China: epidemiological trends, genomic insights, and future directions for optimized management
The incidence and mortality of prostate cancer (PCa) in China have risen sharply in recent years, posing an escalating public health concern. In contrast to Western populations, Chinese patients are more frequently diagnosed at advanced stages, often with metastatic disease and suboptimal survival outcomes. These disparities reflect intrinsic differences in epidemiological patterns, molecular landscapes, and healthcare delivery systems unique to the Chinese context. Nevertheless, prevailing PCa management paradigms, largely derived from Western-centric evidence, remain inadequately calibrated to the biological and clinical realities of Chinese patients. This review provides a comprehensive synthesis of the epidemiology, genomic alterations, clinical presentations, and treatment disparities of PCa in China, highlighting the urgent need for population-specific strategies. Priority areas include the development of ethnically optimized screening protocols, the integration of precision medicine approaches, and the implementation of regionally adapted prevention and early detection programs. Furthermore, expanding participation in clinical trials and accelerating translational research efforts, particularly in multi-omics and biomarker discovery, will be critical to bridging current gaps. By aligning emerging scientific innovations with localized healthcare needs, China holds the potential to reshape its prostate cancer care paradigm, improving outcomes, reducing disparities, and contributing to the global advancement of precision oncology.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
14.20
自引率
0.00%
发文量
0
审稿时长
70 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信